1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Melanoma Drug Market, by Type of Melanoma
6.1. Introduction
6.2. Acral Lentiginous Melanoma
6.3. Lentigo Maligna Melanoma
6.4. Nodular Melanoma
6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Therapy
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.4. Targeted Therapy

8. California Melanoma Drug Market

9. Florida Melanoma Drug Market

10. Illinois Melanoma Drug Market

11. New York Melanoma Drug Market

12. Ohio Melanoma Drug Market

13. Pennsylvania Melanoma Drug Market

14. Texas Melanoma Drug Market

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. AB Sciences
16.2. AbbVie Inc.
16.3. Amgen
16.4. Aptose Biosciences
16.5. Array BioPharma
16.6. AstraZeneca
16.7. AVAX Technologies
16.8. Biogen
16.9. Bristol-Myers Squibb
16.10. Celgene
16.11. CK Life Sciences Int'l
16.12. Daiichi Sankyo Company, Limited
16.13. Eli Lilly
16.14. Enzon Pharmaceuticals Inc.
16.15. Genentech
16.16. GlaxoSmithKline plc
16.17. Incyte
16.18. Janssen Biotech
16.19. Johnson & Johnson
16.20. Merck & Co.
16.21. Novartis
16.22. ONO PHARMACEUTICAL CO. LTD
16.23. Pantarhei Bioscience
16.24. Philogen
16.25. Pierre Fabre
16.26. Polynoma
16.27. Provectus
16.28. Reliance Industries Limited
16.29. Roche
16.30. Sanofi
16.31. Schering-Plough
16.32. Takeda Pharmaceutical

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES MELANOMA DRUG MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES MELANOMA DRUG MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2027
FIGURE 6. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2020 VS 2027 (%)
FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2020 VS 2027 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2027
FIGURE 17. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 18. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES MELANOMA DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 24. UNITED STATES MELANOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 25. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES MELANOMA DRUG MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES MELANOMA DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES MELANOMA DRUG MARKET: SCORES
TABLE 13. UNITED STATES MELANOMA DRUG MARKET: BUSINESS STRATEGY
TABLE 14. UNITED STATES MELANOMA DRUG MARKET: PRODUCT SATISFACTION
TABLE 15. UNITED STATES MELANOMA DRUG MARKET: RANKING
TABLE 16. UNITED STATES MELANOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 17. UNITED STATES MELANOMA DRUG MARKET: MERGER & ACQUISITION
TABLE 18. UNITED STATES MELANOMA DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 19. UNITED STATES MELANOMA DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 20. UNITED STATES MELANOMA DRUG MARKET: INVESTMENT & FUNDING
TABLE 21. UNITED STATES MELANOMA DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 22. UNITED STATES MELANOMA DRUG MARKET: LICENSE & PRICING

Companies Mentioned

AB Sciences
AbbVie Inc.
Amgen
Aptose Biosciences
Array BioPharma
AstraZeneca
AVAX Technologies
Biogen
Bristol-Myers Squibb
Celgene
CK Life Sciences Int'l
Daiichi Sankyo Company, Limited
Eli Lilly
Enzon Pharmaceuticals Inc.
Genentech
GlaxoSmithKline plc
Incyte
Janssen Biotech
Johnson & Johnson
Merck & Co.
Novartis
ONO PHARMACEUTICAL CO. LTD
Pantarhei Bioscience
Philogen
Pierre Fabre
Polynoma
Provectus
Reliance Industries Limited
Roche
Sanofi
Schering-Plough
Takeda Pharmaceutical